<EMPH TYPE="ITAL">SCN5A</EMPH>—A Mechanistic Link Between Inherited Cardiomyopathies and a Predisposition to Arrhythmias?

Abstract

clinical research for decision making in clinical and health policy. JAMA. 2003;290: 1624-1632. 7. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152-1156. 8. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non–ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89-96. 9. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996;77:551-556. 10. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652-659. 11. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med. 2004;350:2196-2198. 12. Roe MT, Ohman EM, Pollack CV Jr, et al. Changing the model of care for patients with acute coronary syndromes. Am Heart J. 2003;146:605-612. 13. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 1999. 14. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health Care System. Washington, DC: National Academies Press; 2000. 15. Brody BA. Ethical issues in clinical trials in developing countries. Stat Med. 2002; 21:2853-2858. 16. Califf RM, Peterson ED, Gibbons RJ, et al; American College of Cardiology; American Heart Association. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol. 2002;40:1895-1901. 17. Vioxx: an unequal partnership between safety and efficacy. Lancet. 2004;364: 1287-1288. 18. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004;292:2647-2650. 19. Califf RM. Defining the balance of risk and benefit in the era of genomics and proteomics. Health Aff. 2004;23:77-87. 20. Yusuf S, Mehta SR, Diaz R, et al. Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and lowmolecular-weight heparin in acute myocardial infarction. Am Heart J. 2004;148: 1068-1078.